Form 4: Silo Pharma CEO Eric Weisblum Acquires 2,500 Shares

Silo Pharma's CEO and President, Eric Weisblum, purchased 2,500 shares of common stock at a price of $0.8387 per share.

Summary

• Eric Weisblum, the CEO and President of Silo Pharma, Inc., acquired 2,500 shares of the company's common stock on December 13, 2024.
• The purchase price was $0.8387 per share.
• Following this transaction, Mr. Weisblum directly owns 187,932 shares of Silo Pharma common stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It reports a routine transaction by an executive. The purchase could be seen as a positive sign, but it is not a major event.

Positives

• The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The reporting requirements are consistent across all companies and are designed to ensure transparency in insider trading.
• The purchase of shares by a CEO is not unusual and can be seen as a sign of confidence in the company's prospects, but it is not a guarantee of future performance.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Silo Pharma, Eric Weisblum, insider trading, share purchase, common stock, SEC Form 4, executive ownership